Key Points Summary Asias GLP1 uptake has lagged the West but is primed for rapid acceleration as obesity rates rise and government urgency grows China and India are driving demand shifts as diets westernise and metabolic disease climbs Cost barriers are falling: local firms in China and India are developing cheaper semaglutide generics, forcing price cuts Mintel forecasts explosive growth, with China potentially becoming the worlds No1 GLP1 market by 2030 Safety fears persist in China (side effects, rebound, semaglutide face) and in India (strict rules on drug promotion) GLP-1 agonist drugs have revolutionised weight loss in the United States and parts of Europe, providing in most cases a highly effective way to manage the ballooning issue of obesity in these markets
Like in women, it blocks estrogens effects in the breast tissue
Los precios pueden variar segn la farmacia, la dosis y las normativas locales
A GLP-1 receptor agonist, semaglutide aids in blood sugar regulation, appetite suppression, and delayed digestion
Many women with PCOS have cells that dont respond effectively to insulin, leading to higher insulin levels in the blood
This rotation pattern allows tissues to fully recover between injections
